aibioJANX Janux Therapeutics, Inc.
Janux Therapeutics (JANX) news
Top story · Aug 6, 2026 · SEC filing 8-K
Janux Therapeutics reports results
Latest Janux Therapeutics news
We have not published a story on Janux Therapeutics yet. When there is news, it will appear here.
What Janux Therapeutics does
Janux Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for cancer using its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr) and Adaptive Immune Response Modulator (ARM) platforms. TRACTr produces T cell engagers with a tumor antigen-binding domain and a CD3 T cell binding domain, and TRACIr produces bispecifics with a tumor antigen-binding domain and a CD28 costimulatory binding domain. Its initial focus is a class of TRACTr therapeutics designed to overcome the healthy tissue immune activation and short half-life that the text says limited earlier T cell engagers in solid tumors. Its first clinical candidate, JANX007, is a prostate-specific membrane antigen (PSMA) TRACTr in a Phase 1 clinical trial in adults with metastatic castration-resistant prostate cancer (mCRPC). The company reported updated interim JANX007 data in December 2024 and updated results in December 2025 showing durability across once-weekly and every-two-week Phase 1a expansion cohorts. It has initiated the first of its planned Phase 1b expansion cohorts to further characterize JANX007 and inform potential registrational development strategies.
| Product or program | What it is | Stage |
|---|---|---|
| JANX007 | PSMA TRACTr T cell engager for metastatic castration-resistant prostate cancer | Phase 1 |
Janux Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $125.9 million | $68.4 million |
| Net income (loss) | -$113.6 million | -$69.0 million |
| Cash from operations | -$82.2 million | -$43.8 million |
| Cash and equivalents | $52.3 million | $430.6 million |
| Short-term investments | $914.2 million | $594.6 million |
Questions about Janux Therapeutics
What is the ticker symbol of Janux Therapeutics?
Janux Therapeutics, Inc. trades under the ticker JANX on NASDAQ.
Where is Janux Therapeutics listed?
Janux Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Janux Therapeutics?
The SEC Central Index Key (CIK) for Janux Therapeutics, Inc. is 1817713. Its filings are on SEC EDGAR.
How many shares does Janux Therapeutics have outstanding?
61,136,773 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Janux Therapeutics listed under?
Our directory records Janux Therapeutics, Inc. under United States.
What does Janux Therapeutics do?
Our directory classifies Janux Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Janux Therapeutics?
The ISIN recorded for Janux Therapeutics, Inc. is US47103J1051.
Does aibio.space cover Janux Therapeutics?
aibio.space lists Janux Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Janux Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What does Janux Therapeutics develop?
Janux Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for cancer using its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr) and Adaptive Immune Response Modulator (ARM) platforms. TRACTr produces T cell engagers with a tumor antigen-binding domain and a CD3 T cell binding domain, and TRACIr produces bispecifics with a tumor antigen-binding domain and a CD28 costimulatory binding domain.
What is JANX007 from Janux Therapeutics?
JANX007: PSMA TRACTr T cell engager for metastatic castration-resistant prostate cancer Stage: Phase 1.
Is Janux Therapeutics profitable?
Janux Therapeutics, Inc. reported a net loss of $113.6 million for the fiscal year ended Dec 31, 2025, and used $82.2 million of cash in operations, per its annual report to the SEC.
How much does Janux Therapeutics spend on research and development?
$125.9 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Janux Therapeutics have?
$970.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is Janux Therapeutics's market cap?
We do not publish live share prices. In its annual report, Janux Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $1.10 billion as of Jun 30, 2025.
Investor discussion: Janux Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported a financing. SEC Form 424B5. Source
Stock chart
SEC filings and registration
- SEC name
- Janux Therapeutics, Inc.
- CIK
- 1817713
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- JANX (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- 10955 VISTA SORRENTO PARKWAY, SAN DIEGO, CA, 92130
- Phone
- (858) 751-4493
- Shares outstanding
- 61,136,773 as of 2026-08-04 (10-Q filed 2026-08-06)
Recent filings
Listing details
- Company
- Janux Therapeutics, Inc.
- Ticker
- JANX
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US47103J1051
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction